Institutional development · Research, innovation and assessment · Italy
Tor Vergata-CNR study finds blood signature in Parkinson's with Alzheimer's markers
Researchers from the University of Rome Tor Vergata, LIFE - Santa Lucia IRCCS and Italy's National Research Council report an immunometabolic profile linked to more severe symptoms in early Parkinson's.
Why it matters: Researchers at Tor Vergata, LIFE - Santa Lucia IRCCS and the CNR's Institute of Translational Pharmacology are behind the newly published Parkinson's blood-signature findings.
The CNR (Consiglio Nazionale delle Ricerche, Italy's National Research Council) said a study by the University of Rome Tor Vergata, LIFE - Santa Lucia IRCCS and the CNR Institute of Translational Pharmacology identified a specific immunometabolic signature in early-stage Parkinson's patients who also show biological indicators of Alzheimer's disease.
The research has been published in the journal npj Parkinson's Disease, according to the CNR.
According to the CNR, the study found changes in inflammatory responses, in the balance between immune cells and in energy-production processes, associated with greater severity of motor and non-motor symptoms.
The CNR said the results open new prospects for identifying different biological profiles of the disease and developing more personalised diagnostic tools and therapies.
Editor’s view
Scott James, Research and Innovation Editor
The study by Tor Vergata, LIFE - Santa Lucia IRCCS and the CNR links an immunometabolic blood profile to more severe symptoms in early Parkinson's patients with Alzheimer's markers; the CNR said the findings could support identifying distinct disease profiles and more personalised diagnostics and therapies.